Orforglipron Powder

Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

Orforglipron binds selectively to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, mimicking the effects of endogenous GLP-1. Unlike peptide-based GLP-1 agonists (e.g., semaglutide), its small molecular structure enables oral bioavailability, eliminating the need for subcutaneous injections. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite by acting on hypothalamic appetite centers.

Glycemic Control: Improves blood sugar regulation by increasing insulin sensitivity and reducing hepatic glucose production, with demonstrated efficacy in lowering HbA1c levels by 1.5-2.0% in patients with type 2 diabetes (T2D).

Weight Management: Induces significant weight loss (average 10-15% of baseline body weight in 52 weeks) by reducing calorie intake and promoting satiety, with effects comparable to injectable GLP-1 agonists.

Cardioprotective Effects: Reduces cardiovascular risk factors by lowering systolic blood pressure, triglyceride levels, and inflammatory markers (e.g., C-reactive protein) in patients with obesity or T2D.

Convenience: Daily oral administration improves patient adherence compared to weekly injectable therapies, addressing a major unmet need in chronic disease management.

Type 2 Diabetes: Approved for use as monotherapy or in combination with other antidiabetic agents (e.g., metformin, SGLT2 inhibitors) to improve glycemic control in adults with inadequately controlled T2D.

Obesity & Overweight: FDA-approved for long-term weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, sleep apnea).

Prediabetes: Investigated in clinical trials for preventing progression to T2D in patients with prediabetes by improving insulin sensitivity and reducing visceral adiposity.

Nonalcoholic Steatohepatitis (NASH): Early studies suggest potential benefits in reducing liver fat accumulation and inflammation, making it a promising candidate for NASH treatment.

Dosage: Typically initiated at 3 mg once daily, titrated up to a maximum of 36 mg daily based on tolerability and therapeutic response.

Side Effects: Most common adverse events are gastrointestinal (nausea, diarrhea, vomiting), which are mild to moderate and diminish over time. Hypoglycemia risk is low when used as monotherapy but may increase with concurrent insulin or sulfonylurea use.

Contraindications: Not recommended for patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

Other Nootropics Raw Material Also Available

Delivery Time:Around 3-5 workdays after your payment.

Package:1kg/aluminium foil bag;25Kgs in fiber-drums with two-plastic bags inside

Net Weight:25kgs/Drum/Gross Weight:28kgs/Drum

Drum Size & Volume:I.D.42cm × H52cm,0.08 m³/Drum

Storage:Stored in dry and cool place,keep away from strong light and heat.

Shelf Life:Two years when properly stored.

Hot Tags: orforglipron powder, China orforglipron powder manufacturers, suppliers, factory, ALA Powder for Cellular Health, Dihydroberberine for Weight Loss, Melatonin Bulk for Supplement Manufacturing, Neomycin Sulfate for Post op Infection Prevention, Povidone Iodine for Sterilization, Tianeptine Sodium Salt for Anxiety and Stress